# A Study of PRA052 in Healthy Volunteers

> **NCT05603182** · PHASE1 · COMPLETED · sponsor: **Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 96 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** PRA052
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05603182
- **Lead sponsor:** Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-07
- **Primary completion:** 2024-02-21
- **Final completion:** 2024-02-21
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2024-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05603182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05603182, "A Study of PRA052 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05603182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*